ClinicalTrials.gg
WithdrawnNCT03094468Updated Jan 10, 2018

Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis

A Phase 3 interventional study of P-3058 (terbinafine hydrochloride 10%) and Vehicle of P-3058 in Onychomycosis of Toenail, sponsored by Polichem S.A.. Withdrawn at 26 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-01-10.

Sponsored by Polichem S.A. (part of Almirall, S.A.) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Project development priorities changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing terbinafine in Onychomycosis — 1 open to participants now, 2 under way, 1 of them phase 3. Terbinafine · Onychomycosis.

Enrollment
19th of 19
0 · median 100
Started
2017
with 2 others
Phase 3
10 of 20
none open now
Registered
14th of 20
by date

Among the 20 studies testing terbinafine in Onychomycosis, this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2017, is one of 10 in phase 3, and was the 14th registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

1 of the 20 studies testing terbinafine in Onychomycosis is open now. Recruiting first, the newest first:

About terbinafine

Terbinafine: first FDA approval 1992 (LAMISIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing terbinafine in Onychomycosis, or all of them as a file.
02

Study summary

The aim of this phase III study is to establish the efficacy and safety of P-3058 (terbinafine 10% nail solution) topically administered once weekly in patients with onychomycosis in comparison to the Vehicle in a double-blind fashion. The overall treatment period will be of 48 weeks.

Read the detailed description

The study will consist of a screening phase, a treatment phase of 48 weeks and a 12-week follow-up. Patients affected by mild to-moderate distal lateral subungual onychomycosis (DLSO) on a target great toenail will be included in the study. Clinical as well as mycology assessments will be performed throughout the whole study. Safety will be monitored by recording any adverse event and evaluating local tolerability.

03

Conditions studied

  • Onychomycosis of Toenail

Browse trials for

Keywords

  • terbinafine nail solution
  • nail fungal infection
  • topical antifungal drug
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written before starting any study related procedures.
  • Patients aged 12 and older of any race.
  • Males or females.
  • Outpatients.
  • Clinically diagnosed mild-to-moderate distal lateral subungual onychomycosis (DLSO) of at least one great toenail (the "target nail") at the Screening visit (V1).
  • Patients with onychomycosis involving ≥ 20% to ≤ 50% of the area of the target great toenail.
  • Patients with a positive KOH examination.
  • Patients with positive culture for dermatophyte(s).
  • Evidence of target great toenail growth reported by the patient defined as at least monthly nail clipping.

Exclusion criteria

Exclusion Criteria:

  • Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period.
  • Patients with history of allergic reactions to terbinafine or its .
  • Use of any drug/device or participation in a previous clinical trial within four weeks prior to Screening visit (V1).
  • Patients using nail polish or other nail cosmetic product on the concerned nails from at least 24 hours prior to Screening visit (V1) until the end of the study.
  • Use of systemic antifungal drugs in the 24 weeks prior to Screening visit (V1) or non-responsive to systemic antifungal therapy for onychomycosis.
  • Nail application of topical antifungal drugs or device in the 4 weeks prior to Screening visit (V1).
  • Presence of any nail infections other than dermatophyte.
  • Presence of onychodystrophy that could interfere with clinical assessments.
  • Presence of "yellow spikes" on the target nail.
  • Presence of dermatophytoma on the target nail.
  • Presence of nail thickness exceeding 2 mm.
  • Patients with proximal subungual involvement (marker of patient).
  • Patients with severe plantar or moccasin tinea pedis (defined by blistering, pustules or inability to ambulate).
  • Patients with nail abnormalities due to conditions like psoriasis, lichen planus, immune dysfunction, collagen-vascular diseases, peripheral vascular disease.
  • Patients with less than 2 years.
  • Chemotherapy, immunosuppressive therapy in the 12 weeks prior to Screening visit (V1).
  • Systemic , antimetabolites and immune-stimulants therapy in the 4 weeks prior to Screening visit (V1).
  • infection or any other immunodeficiency.
  • Alcohol or substance abuse.
  • Patients/parents (or legal guardian) unable to understand the procedures and purposes of the study.
  • Any other condition that, in the opinion of the Investigator, would prevent the subject from effectively participating in the study, place the subject at risk or effect the assessment of efficacy and safety of the study medication.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    P-3058

    Drug: P-3058 (terbinafine hydrochloride 10%)

  • Placebo comparator
    Vehicle

    Drug: Vehicle of P-3058

Interventions

  • Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.

  • DrugVehicle of P-3058

    Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.

06

What researchers measure

Primary outcomes

  1. Rate of complete cure at Week 60

    Defined as composite of negative KOH microscopy and negative culture for dermatophytes and no residual clinical involvement (nail totally clear) of the target nail.

    Time frame: Baseline - Week 60

Secondary outcomes

  1. Responder rate at Week 60

    Defined as negative Potassium Hydroxide (KOH) microscopy and negative culture for dermatophytes and ≤ 10% residual involvement of the target toenail)

    Time frame: Baseline - Week 60

  2. Mycological cure rate at Week 60

    Defined as negative Potassium Hydroxide (KOH) microscopy and negative culture for dermatophytes of the target nail.

    Time frame: Baseline - Week 60

Other outcomes

  1. Negative culture rate for dermatophytes of the target nail at Week 60

    Time frame: Baseline - Week 60

  2. Onychomycosis quality of life

    The questionnaire ONYCHO (Toenail from Mapi Research Trust) will be administered at Week 0, at Week 48 and at Week 60 or at the discontinuation visit.

    Time frame: Baseline - Week 48, Week 60

07

Study locations

26 sites
  • Polichem Investigation Site no 45
    North Hollywood, California 91606, United States
  • Polichem Investigation Site no 5
    Oceanside, California 92056, United States
  • Polichem Investigation Site no 39
    San Diego, California 92123, United States
  • Polichem Investigation Site no 2
    Hialeah, Florida 33012, United States
  • Polichem Investigation Site no 23
    Jacksonville, Florida 32204, United States
  • Polichem Investigation Site no 22
    Miami, Florida 33176, United States
  • Polichem Investigation Site no 52
    Louisville, Kentucky 40202, United States
  • Polichem Investigation Site no 41
    Portsmouth, New Hampshire 03801, United States
  • Polichem Investigation site no 1
    New York, New York 10025, United States
  • Polichem Investigation Site no 44
    Cincinnati, Ohio 45249, United States
  • Polichem Investigation Site no 40
    Norman, Oklahoma 71071, United States
  • Polichem Investigation Site no 14
    Oklahoma City, Oklahoma 73103, United States
  • Polichem Investigation Site no 10
    Austin, Texas 78731, United States
  • Polichem Investigation Site no 11
    Dallas, Texas 75234, United States
  • Polichem Investigation Site no 43
    Dallas, Texas 75246, United States
  • Polichem Investigation Site no 6
    Fort Worth, Texas 76107, United States
  • Polichem Investigation Site no 12
    Houston, Texas 77055, United States
  • Polichem Investigation Site no 4
    Houston, Texas 77081, United States
  • Polichem Investigation Site no 42
    Pflugerville, Texas 78660, United States
  • Polichem Investigation Site no 53
    San Antonio, Texas 78229, United States
  • Polichem Investigation Site no 54
    San Antonio, Texas 78249, United States
  • Polichem Investigation site no 3
    Calgary, Alberta T2G 1B1, Canada
  • Polichem Investigation Site no 8
    Edmonton, Alberta T5K 1X3, Canada
  • Polichem Investigation Site no 13
    Mississauga, Ontario L5H 1G9, Canada
  • Polichem Investigation Site no 9
    Richmond Hill, Ontario L4C 9M7, Canada
  • Polichem Investigation Site no 7
    Toronto, Ontario M9W 4L6, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2017; primary completion for Oct 2019, 29 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2017
First posted
Mar 29, 2017
StartEst.
May 2017
Primary completionEst.
Oct 2019
CompletionEst.
Dec 2019
Last update
Jan 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03094468
Lead sponsor
Polichem S.A.
Collaborators
Almirall, S.A.
Responsible party
Sponsor
First posted
Mar 29, 2017
Start date
May 2017 (estimated)
Primary completion
Oct 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Jan 10, 2018

Study contacts

Maurizio Caserini, MD
study director · Polichem SA

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terbinafine

Start the discussion